Genaera : MedImmune Initiation of Phase 2A Trial of Antibody Targeting Interleukin-9 in Patients with Asthma

March 18th, 2008 -- Genaera Corporation (NASDAQ: GENR) reported that development partner, MedImmune, has initiated its fourth phase 2a clinical trial of MEDI-528, an anti-IL-9 monoclonal antibody (MAb) targeting interleukin-9 (IL-9), in patients with asthma. This clinical trial is designed to assess the potential of MEDI-528 in patients with stable asthma and exercise-induced bronchoconstriction. Genaera and MedImmune entered into a research collaboration and licensing agreement for this program in 2001.MedImmune is currently evaluating MEDI-528 in patients with asthma in a series of phase 2 clinical trials. The goal of the current phase 2a trial is to assess the safety and tolerability of multiple fixed escalating doses of MEDI-528 in adult patients with stable asthma and exerciseinduced bronchoconstriction... Genaera's Press Release - MedImmune's Press Release -